Company / PP&E (Net)
Emergent BioSolutions Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$205.4M
FY2025
5-year range
$205.4M / $817.6M
FY2021-FY2025
Trend
-24.1%
vs FY2024
Sector context
#30 of 193
Health Care
What the data says
Emergent BioSolutions Inc.'s pp&e (net) of $205M is higher than 84% of companies in the Health Care sector (FY2025). PP&E (Net) has declined for 3 consecutive years, from $818M in FY2022 to $205M in FY2025.
Based on SEC 10-K filings.
$205M in FY2025 with a 5-year CAGR of -20.4%. Top quartile in the Health Care sector.
Declined from $383M to $205M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -36.9%
- 5-Year CAGR
- -20.4%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 193This company $205.4M Sector average $777.6M
▼
-73.6% below sector average
Key checks
Key Insights
- Emergent BioSolutions Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of -20.4%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 24.1% year-over-year.
- Ranks #30 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $205.4M | -24.1% |
| FY2024 | $270.6M | -29.3% |
| FY2023 | $382.8M | -53.2% |
| FY2022 | $817.6M | +2.2% |
| FY2021 | $800.1M | +24.2% |
| FY2020 | $644.1M | +18.8% |
| FY2019 | $542.3M | +6.3% |
| FY2018 | $510.2M | +25.3% |
| FY2017 | $407.2M | +8.2% |
| FY2016 | $376.4M | +14.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026